TORONTO, May 2, 2013 /PRNewswire/ - Celestica Inc. (NYSE, TSX: CLS), a global leader in the delivery of end-to-end product lifecycle solutions, is pleased to announce that its Oradea, Romania facility is now certified to ISO 13485.
ISO 13485 is an internationally recognized quality management system (QMS) standard for the medical industry. It requires strict adherence to quality and reliability standards in healthcare, including corrective actions to drive consistency for medical devices.
"This is an important milestone for Celestica as we extend our medical device manufacturing and engineering services in Europe, strengthening Celestica's global supply chain network," said Kevin Walsh, Vice President, Celestica HealthTech. "This certification is a further demonstration of Celestica's ongoing commitment to make investments to achieve market-leading quality and regulatory compliance for our global healthcare customers."
The Oradea, Romania facility is one of Celestica's ISO 13485-certified Centers of Excellence for medical manufacturing, joining Portland, OR, United States; San Jose, CA, United States; Galway, Ireland; Valencia, Spain; Suzhou, China; Johor Bahru, Malaysia; and Serangoon, Singapore.In addition to ISO 13485 certification, Celestica is also fully qualified to meet other rigorous standards of the medical industry around the globe, such as ISO 9001, ISO 14001, Class 7 Clean Rooms, FDA-registered sites, robust cGMP and QS processes, and QSR/cGMP-compliant facilities. About Celestica Celestica is dedicated to delivering end-to-end product lifecycle solutions to drive our customers' success. Through our simplified global operations network and information technology platform, we are solid partners who deliver informed, flexible solutions that enable our customers to succeed in the markets they serve. Committed to providing a truly differentiated customer experience, our agile and adaptive employees share a proud history of demonstrated expertise and creativity that enhances our customers' ability to overcome complex challenges.